Related Experiment Videos
Ethical issues in drug selection for schizophrenia
1Department of Psychiatry and Pharmacy, Clarke Institute of Psychiatry, Toronto, Ontario.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|September 1, 1993
Summary
New antipsychotic medications offer potential benefits for schizophrenia treatment but require realistic assessment of their efficacy and side effects. Clinicians must balance treatment complexities with fostering patient insight and collaboration.
Area of Science:
- Pharmacology
- Psychiatry
- Medical Ethics
Background:
- Neuroleptics, introduced over 40 years ago, revolutionized schizophrenia treatment but are associated with significant side effects.
- The development of new atypical antipsychotics, like clozapine, necessitates a realistic evaluation beyond viewing them as cures.
- Schizophrenia treatment involves complex legal and ethical considerations regarding informed consent due to potential drug toxicities.
Purpose of the Study:
- To critically assess the advantages of new atypical neuroleptics.
- To evaluate their impact on positive and negative symptoms of schizophrenia.
- To analyze potential adverse effects and cost-benefit ratios.
Main Methods:
- Critical evaluation of existing literature on atypical antipsychotics.
- Analysis of effects on positive and negative symptomatology.
- Assessment of adverse effects and cost-benefit.
Main Results:
- New atypical neuroleptics require realistic appraisal of their benefits and risks.
- Evaluation should encompass efficacy, side effects, and economic factors.
- Challenges in obtaining informed consent persist due to drug toxicities.
Conclusions:
- Clinicians should realistically assess new antipsychotics, considering both benefits and drawbacks.
- Fostering patient insight and a collaborative approach is crucial for managing schizophrenia.
- Despite treatment challenges, a patient-centered strategy is vital for coping with schizophrenia.
Keywords:
Mental Health Therapies